The clinical effectiveness agency for England and Wales says that it now favors the use of thalidomide and bortezomib as options for the first-line treatment of multiple myeloma.In draft guidance issued June 2, the National Institute for Health and Clinical Effectiveness recommended that oral thalidomide, in combination with an alkylating agent and a corticosteroid, should be a treatment option for people who are not, because of age or comorbidities, eligible for high-dose chemotherapy with stem...